Healthcare & Life Sciences

December 06 2017
Joanne van Harmelen Draft IP Policy Phase 1 – part two: access to medicines, state 'walk-in' rights and parallel import

South Africa - ENSafrica

The recently published Draft IP Policy Phase 1 2017 includes a number of provisions relating to parallel import and state 'walk-in' rights for access to affordable medicines. Although there are complex issues surrounding access to affordable medicines, the inclusive process that the government has used in the implementation of the new policy is encouraging.

Author: Joanne van Harmelen
Read more
William Sarraille California passes sweeping prescription drug price transparency law and co-pay coupon ban

USA - Sidley Austin LLP

California recently passed two bills with significant implications for pharmaceutical manufacturers: one imposing prescription drug price transparency requirements and another prohibiting certain types of co-pay coupon and other prescription drug discounting programmes that lower patient cost-sharing amounts for prescription drugs.

Authors: William Sarraille, Meenakshi Datta, Trevor L Wear
Read more

Recent updates

Katie Lee Court rejects Apotex's application for judicial review of omeprazole magnesium tablet submission

Canada - Smart & Biggar/Fetherstonhaugh

Author: Katie Lee
Jonas Löfgren Pharmaceutical companies request Patent and Registration Office to reassess decisions

Sweden - Advokatfirman Lindahl

Author: Jonas Löfgren
Elysangela de Oliveira Rabelo Creating healthcare solutions with blockchain technology

Brazil - TozziniFreire Advogados

Author: Elysangela de Oliveira Rabelo
Jaime L M Jones District court dismisses False Claims Act claims based on no evidence of falsity

USA - Sidley Austin LLP

Authors: Jaime L M Jones, Whitney C Nebolisa

Upcoming event

2nd Pharma and Biotech IP Summit

February 8 2018 - London

IAM’s second annual Pharma and Biotech IP Summit will once again bring together leading IP experts from across life sciences. Last year’s Brexit vote added further uncertainty to an already precarious life sciences IP market and with the Unified Patent Court now thrown into confusion, the political and legislative landscape is one to navigate with caution. Against this backdrop, attendees will hear the latest IP strategies for thriving at a time when regulatory and legislative changes are significantly impacting business models.


For more details go to:
https://goo.gl/j6u71g

ONLINE MEDIA PARTNERS